NewLink Genetics (NLNK) Stock Rating Lowered by Zacks Investment Research

NewLink Genetics (NASDAQ:NLNK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.

According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “

Several other research firms have also recently weighed in on NLNK. Stifel Nicolaus raised their price target on NewLink Genetics from $14.00 to $29.00 and gave the company a “buy” rating in a report on Monday, September 11th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $26.00 price target on shares of NewLink Genetics in a report on Friday, September 8th. ValuEngine cut NewLink Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. Robert W. Baird raised NewLink Genetics from a “neutral” rating to an “outperform” rating and raised their price target for the company from $8.00 to $22.00 in a report on Friday, September 8th. Finally, Jefferies Group raised NewLink Genetics from a “hold” rating to a “buy” rating and raised their price target for the company from $7.00 to $26.00 in a report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $23.29.

Shares of NewLink Genetics (NLNK) opened at $9.00 on Thursday. NewLink Genetics has a 1-year low of $5.90 and a 1-year high of $25.17.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company grew its position in NewLink Genetics by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 556 shares during the last quarter. Advisor Group Inc. grew its position in NewLink Genetics by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 600 shares during the last quarter. First Trust Advisors LP grew its position in NewLink Genetics by 11.1% during the 2nd quarter. First Trust Advisors LP now owns 28,598 shares of the biotechnology company’s stock worth $210,000 after acquiring an additional 2,859 shares during the last quarter. Wells Fargo & Company MN grew its position in NewLink Genetics by 1.8% during the 2nd quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock worth $1,219,000 after acquiring an additional 2,865 shares during the last quarter. Finally, State Street Corp grew its position in NewLink Genetics by 1.2% during the 2nd quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after acquiring an additional 4,630 shares during the last quarter. Institutional investors and hedge funds own 52.63% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2018/01/06/newlink-genetics-nlnk-stock-rating-lowered-by-zacks-investment-research.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

What are top analysts saying about NewLink Genetics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NewLink Genetics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit